What the program is
Atherosclerosis — the buildup of plaque in coronary arteries — is the disease behind most heart attacks and a significant fraction of strokes and heart failure cases. It is also one of the slowest diseases in medicine: the plaque that causes a heart attack at 60 has been building since the patient was in their 30s. That is the opportunity. The window for intervention is decades wide, but only if you measure the right things and act on them early.
Longevity cardiology is the structured approach to using that window: identify each individual's true cardiovascular risk earlier and more precisely than the standard primary-care calculation does, and treat that risk before it becomes disease. This is what the evidence supports — and increasingly what specialty cardiology societies recommend — but it is not what most patients get from a once-a-year primary-care visit.
What we look at that standard care typically does not
Apolipoprotein B (apoB)
LDL cholesterol is the input most people know. apoB is the more accurate one — it directly counts the atherogenic particles in your bloodstream. In about a third of patients, the apoB and LDL numbers tell meaningfully different stories, and the apoB number is the one that better predicts events.
Lipoprotein(a) — Lp(a)
A genetically determined risk factor most patients have never had measured. About 20% of the population has an elevated Lp(a), which confers significantly higher lifetime risk of heart attack and aortic valve disease independent of cholesterol numbers. It is a one-time blood test. Knowing your Lp(a) status changes how aggressively we treat everything else, and new Lp(a)-lowering therapies are in late-stage trials.
Coronary artery calcium (CAC) scoring
A low-radiation CT scan that directly visualizes plaque calcification in your coronary arteries. A zero score in your 50s is one of the strongest reassurance signals in cardiology. A non-zero score restratifies your risk in a way no blood test can match, and it is the single piece of information that most often changes our treatment plan.
Polygenic risk scoring
A genetic risk score for coronary artery disease — a single one-time test that summarizes the combined effect of hundreds of common variants. It identifies people whose inherited risk diverges from their conventional risk factors. The data supporting clinical use of polygenic risk scores in cardiology has matured significantly in the last few years.
Inflammation markers
High-sensitivity CRP and, when indicated, more specific markers. Persistent inflammation is an independent driver of cardiovascular events, and new anti-inflammatory therapies are FDA-approved for secondary prevention.
What the program is not
It is not a "wellness" panel or a vitamin-and-supplement consultation. It is also not concierge medicine in the membership-fee sense. Every test we order has a specific evidence-based reason it changes the plan. We do not order what will not change a decision.
Why Dr. Deo
Dr. Deo's clinical training is in cardiology — including the interventional, imaging, and outpatient sides — at Harvard-affiliated institutions. His research background is in applying AI and genomics to cardiology, including coauthoring some of the foundational work on machine-learning interpretation of echocardiograms. That dual background is why this program is structured around the evidence base and the technology that actually moves outcomes — not the version that just looks impressive.